PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults

PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults

The pharmacologic inhibition of proprotein convertase subtilisin-kexin type 9 (PCSK9) lowers lipoprotein (a) [Lp(a)] concentrations. However, the impact of genetic PCSK9 loss-of-function variants (LOFVs) on Lp(a) is uncertain. We determined the association of PCSK9 LOFVs with Lp(a) measures among bl...

Full description

Bibliographic Details
Main Authors:	Matthew T. Mefford, Santica M. Marcovina, Vera Bittner, Mary Cushman, Todd M. Brown, Michael E. Farkouh, Sotirios Tsimikas, Keri L. Monda, J. Antonio G. López, Paul Muntner, Robert S. Rosenson
Format:	Article
Language:	English
Published:	Elsevier 2019-11-01
Series:	Journal of Lipid Research
Subjects:	proprotein convertase subtilisin-kexin type 9 lipoprotein (a) apolipoprotein oxidized phospholipids epidemiology
Online Access:	http://www.sciencedirect.com/science/article/pii/S0022227520322926

Similar Items

PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE[S]
by: Brandon Ason, et al.
Published: (2014-11-01)

Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice
by: Yi Luo, et al.
Published: (2009-08-01)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
by: Dennis T. Ko, et al.
Published: (2018-11-01)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
by: Olga Afanasieva, et al.
Published: (2020-10-01)

Functional analysis of sites within PCSK9 responsible for hypercholesterolemias⃞
by: Shilpa Pandit, et al.
Published: (2008-06-01)

ASSOCIATION OF POLYMORPHISM IN PCSK9 GENE WITH LIPID PR OFILE IN RUSSIAN POPULATION
by: K. S. Astrakova, et al.
Published: (2016-06-01)

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]
by: Frederick J. Raal, et al.
Published: (2016-06-01)

Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors
by: Øystein L. Holla, et al.
Published: (2011-10-01)

Use of Low‐Density Lipoprotein–Lowering Therapies Before and After PCSK9 Inhibitor Initiation
by: Jennifer A. Rymer, et al.
Published: (2020-05-01)

High-Throughput Screening Identifies MicroRNAs Regulating Human PCSK9 and Hepatic Low-Density Lipoprotein Receptor Expression
by: Coen van Solingen, et al.
Published: (2021-07-01)

Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia
by: R. Huijgen, et al.
Published: (2012-05-01)

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”
by: Payal Kohli, et al.
Published: (2016-05-01)

Physical activity to reduce PCSK9 levels
by: Amedeo Tirandi, et al.
Published: (2022-08-01)

The PCSK9 decade
by: Gilles Lambert, et al.
Published: (2012-12-01)

Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population
by: Ilaria Guella, et al.
Published: (2010-11-01)

PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis
by: Qianyun Guo, et al.
Published: (2020-09-01)

The predictive utility of circulating PCSK9 levels on diabetes mellitus
by: Jia Peng, et al.
Published: (2021-02-01)

Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients
by: Bruce A. Warden, PharmD, et al.
Published: (2020-03-01)

Levels of proprotein convertase subtilisin/kexin type 9 in patients with acute myocardial infarction
by: A. D. Gimadeeva, et al.
Published: (2020-03-01)

PCSK9 Biology and Its Role in Atherothrombosis
by: Cristina Barale, et al.
Published: (2021-05-01)

Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells[S]
by: Aiqin Cao, et al.
Published: (2011-03-01)

The association of the PCSK9 rs562556 polymorphism with serum lipids level: a meta-analysis
by: Junlan Chuan, et al.
Published: (2019-04-01)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
by: Michael D. Shapiro, et al.
Published: (2019-02-01)

Cell-based, bioluminescent assay for monitoring the interaction between PCSK9 and the LDL receptor
by: Sarah J. Duellman, et al.
Published: (2017-08-01)

Editorial: PCSK9: Importance in Physiology and Pathophysiology
by: Rainer Schulz, et al.
Published: (2021-07-01)

PCSK9 gene participates in the development of primary dyslipidemias
by: Matías-Pérez D, et al.
Published: (2021-07-01)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
by: Aureli Luquero, et al.
Published: (2021-03-01)

PCSK9 inhibitors in clinical practice: Novel directions and new experiences
by: Loukianos S. Rallidis, et al.
Published: (2020-07-01)

ASSOCIATION OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) WITH PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) IN FAMILIAL HYPERCHOLESTEROLEMIA
by: K. S. Benimetskaya, et al.
Published: (2019-03-01)

Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody[S]
by: Krista M. Schroeder, et al.
Published: (2015-11-01)

The circulating furin-cleaved/mature PCSK9 ratio has a potential prognostic significance in statin-naïve patients with acute ST elevation myocardial infarction
by: Jun Sawaguchi, et al.
Published: (2022-12-01)

Efficacy of Evolocumab in Patients with Hypercholesterolemia
by: Xuan Jin, et al.
Published: (2020-12-01)

Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia[S]
by: Victor Sokolov, et al.
Published: (2019-09-01)

The Impact of PCSK9 Gene Polymorphisms on Ischemic Stroke: A Systematic Review and Meta-Analysis
by: Jianhong Wang, et al.
Published: (2024-03-01)

In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction
by: Bowen Lou, et al.
Published: (2022-10-01)

Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report
by: Yuki Awanami, et al.
Published: (2017-07-01)

Prognostic Impacts of LL-37 in Relation to Lipid Profiles of Patients with Myocardial Infarction: A Prospective Cohort Study
by: Runzhen Chen, et al.
Published: (2022-10-01)

Circulating PCSK9 levels and 2-hPG are positively correlated in metabolic diseases in a Chinese Han population
by: Wen Guo, et al.
Published: (2018-01-01)

What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis
by: Chengfeng Qiu, et al.
Published: (2017-06-01)

Association and differences in genetic polymorphisms in PCSK9 gene in subjects with lacunar infarction in the Han and Uygur populations of Xinjiang Uygur Autonomous Region of China
by: Deng-feng Han, et al.
Published: (2017-01-01)